Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer

T. C. Merigan, J. G. Gallagher, Richard B Pollard, A. M. Arvin

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Because of encouraging results when human leukocyte interferon was given for 5 to 7 days to treat early localized herpes zoster in patients with cancer, a small placebo-controlled, randomized, double-blind trial was set up involving only 48 h of therapy. In this trial, there was no effect on acute pain or disease progression in the primary dermatome. However, a modest but significant effect was noted in that distal cutaneous spread was diminished in the treated patients compared with the controls and the treated patients had diminished severity and duration of postherpetic neuralgia. No evidence of impairment in varicella-zoster-specific lymphocyte transformation was observed in interferon-treated patients.

Original languageEnglish (US)
Pages (from-to)193-195
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume19
Issue number1
StatePublished - 1981
Externally publishedYes

Fingerprint

Herpes Zoster
Interferon-alpha
Neoplasms
Postherpetic Neuralgia
Chickenpox
Acute Pain
Acute Disease
Therapeutics
Lymphocyte Activation
Interferons
Disease Progression
Placebos
Skin

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer. / Merigan, T. C.; Gallagher, J. G.; Pollard, Richard B; Arvin, A. M.

In: Antimicrobial Agents and Chemotherapy, Vol. 19, No. 1, 1981, p. 193-195.

Research output: Contribution to journalArticle

@article{84f88474b1cc4869a01ecad3643b37fc,
title = "Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer",
abstract = "Because of encouraging results when human leukocyte interferon was given for 5 to 7 days to treat early localized herpes zoster in patients with cancer, a small placebo-controlled, randomized, double-blind trial was set up involving only 48 h of therapy. In this trial, there was no effect on acute pain or disease progression in the primary dermatome. However, a modest but significant effect was noted in that distal cutaneous spread was diminished in the treated patients compared with the controls and the treated patients had diminished severity and duration of postherpetic neuralgia. No evidence of impairment in varicella-zoster-specific lymphocyte transformation was observed in interferon-treated patients.",
author = "Merigan, {T. C.} and Gallagher, {J. G.} and Pollard, {Richard B} and Arvin, {A. M.}",
year = "1981",
language = "English (US)",
volume = "19",
pages = "193--195",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer

AU - Merigan, T. C.

AU - Gallagher, J. G.

AU - Pollard, Richard B

AU - Arvin, A. M.

PY - 1981

Y1 - 1981

N2 - Because of encouraging results when human leukocyte interferon was given for 5 to 7 days to treat early localized herpes zoster in patients with cancer, a small placebo-controlled, randomized, double-blind trial was set up involving only 48 h of therapy. In this trial, there was no effect on acute pain or disease progression in the primary dermatome. However, a modest but significant effect was noted in that distal cutaneous spread was diminished in the treated patients compared with the controls and the treated patients had diminished severity and duration of postherpetic neuralgia. No evidence of impairment in varicella-zoster-specific lymphocyte transformation was observed in interferon-treated patients.

AB - Because of encouraging results when human leukocyte interferon was given for 5 to 7 days to treat early localized herpes zoster in patients with cancer, a small placebo-controlled, randomized, double-blind trial was set up involving only 48 h of therapy. In this trial, there was no effect on acute pain or disease progression in the primary dermatome. However, a modest but significant effect was noted in that distal cutaneous spread was diminished in the treated patients compared with the controls and the treated patients had diminished severity and duration of postherpetic neuralgia. No evidence of impairment in varicella-zoster-specific lymphocyte transformation was observed in interferon-treated patients.

UR - http://www.scopus.com/inward/record.url?scp=0019505435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019505435&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 193

EP - 195

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

ER -